Curanex Pharmaceuticals Inc CURX
Curanex Pharmaceuticals Inc (Nasdaq: CURX) is a GI/hepatology drug developer. Its lead program, Phyto-N, is in Pre-clinical for Ulcerative colitis (lead); also atopic dermatitis, rheumatoid arthritis, gout, diabetic foot, cancer cachexia. Its next catalyst on record is Phyto-N: IND submission for ulcerative colitis (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Phyto-N — IND submission for ulcerative colitis (Q4 2026). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Phyto-N (botanical extract) | Ulcerative colitis (IND planned Q4 2026) | unclear | Pre-clinical |
| Phyto-N | Cancer cachexia (second core indication) | unclear | Pre-clinical |
| Phyto-N | Atopic dermatitis, rheumatoid arthritis, gouty arthritis, diabetic foot | unclear | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other pre-clinical GI/hepatology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.